HSBC Starts Agilent (A) at Buy

HSBC analyst Sidharth Sahoo initiates coverage on Agilent (NYSE: A) with a Buy rating and a price target of $180.00.

The analyst comments: "Agilent is a global leader in life sciences and diagnostics, providing analytical instruments, software, services, and consumables that support scientific research, quality assurance, and clinical diagnostics in laboratories around the world. Agilent falls into our “quality growth” bucket. Agilent retained its 5-7% medium-term guidance at a time when larger peers have trimmed theirs to 3-6%.

In our view, Agilent is well-positioned for sustained earnings growth, supported by; 1) the ongoing liquid chromatography (LC) and mass spectrometry (MS) replacement cycle, 2) high-growth CDMO modalities (oligonucleotides, peptides/GLP-1s, mRNA), and 3) margin recovery through the “Ignite” programme. Combined with improving pharma and biotech sentiment, and diversified regional growth, these factors underpin strong prospects in FY26-27. Expanding recurring revenue and secular PFAS workflow expansion also support the long-term growth potential."

For an analyst ratings summary and ratings history on Agilent click here. For more ratings news on Agilent click here.

Shares of Agilent closed at $139.64 yesterday.

You May Also Be Interested In